BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 26016480)

  • 21. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
    Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
    Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
    Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.
    Tsutsumi K; Sato N; Tanabe R; Mizumoto K; Morimatsu K; Kayashima T; Fujita H; Ohuchida K; Ohtsuka T; Takahata S; Nakamura M; Tanaka M
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S491-9. PubMed ID: 21837532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC).
    Sun Y; Cao S; Li Z; Liu X; Xu J; Tian Y; Shen S; Zhou Y
    Int J Med Sci; 2021; 18(9):2051-2062. PubMed ID: 33850476
    [No Abstract]   [Full Text] [Related]  

  • 26. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
    PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
    Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
    Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma.
    Ben QW; Wang JC; Liu J; Zhu Y; Yuan F; Yao WY; Yuan YZ
    Ann Surg Oncol; 2010 Aug; 17(8):2213-21. PubMed ID: 20162456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
    Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB
    Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum EpCAM expression in pancreatic cancer.
    Gebauer F; Struck L; Tachezy M; Vashist Y; Wicklein D; Schumacher U; Izbicki JR; Bockhorn M
    Anticancer Res; 2014 Sep; 34(9):4741-6. PubMed ID: 25202052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma.
    Gao Y; Wang M; Guo X; Hu J; Chen TM; Finn SMB; Lacy J; Kunstman JW; Cha CH; Bellin MD; Robert ME; Desir GV; Gorelick FS
    PLoS One; 2021; 16(9):e0250539. PubMed ID: 34587190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
    Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
    Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarcinoma.
    Lockney NA; Zhang M; Lu Y; Sopha SC; Washington MK; Merchant N; Zhao Z; Shyr Y; Chakravarthy AB; Xia F
    J Gastrointest Cancer; 2015 Dec; 46(4):390-8. PubMed ID: 26385349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-specific survival in pancreatic ductal adenocarcinoma.
    Kimura T; Kitada S; Uramoto H; Zhi L; Kawatsu Y; Takeda T; Horie S; Nabeshima A; Noguchi H; Sasaguri Y; Izumi H; Kohno K; Yamada S
    Histol Histopathol; 2015 Feb; 30(2):193-204. PubMed ID: 25108120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic significance of clinicopathological features and apoptosis inhibitor proteins in pancreas ductal adenocarcinoma.
    Argon A; Nart D; Oruç N; Coker A; Ozütemiz O
    Acta Gastroenterol Belg; 2014 Jun; 77(2):229-34. PubMed ID: 25090821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ
    Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.